First in Human, Dose Escalation Study of AN4005

Open-label, multicenter, phase 1 study to investigate the safety, tolerability, and PK of AN4005 in patients with advanced tumors. This study is a first-in-human, dose escalation study with the objective to establish the MTD and/or RP2D of AN4005. Except for Dose Level 0 (50 mg), a traditional "3 + 3 design" will be utilized for dose finding with dose escalation and/or de-escalation as appropriate.

Trial Details

NCT ID
NCT04999384
Phase
PHASE1
Sponsor
Adlai Nortye Biopharma Co., Ltd.
Status
RECRUITING
Cancer Type
Lymphoma
Interventions
  • AN4005-dose level 0
  • AN4005-dose level 1
  • AN4005-dose level 2
  • AN4005-dose level 3
  • AN4005-dose level 4
  • AN4005-food effect
Locations (sample)
  • Hackensack, New Jersey, United States|40.88593,-74.04347
  • The Bronx, New York, United States|40.84985,-73.86641
  • Greenville, South Carolina, United States|34.85262,-82.39401
  • Fairfax, Virginia, United States|38.84622,-77.30637
  • Beijing, Beijing Municipality, China|39.9075,116.39723

Key Eligibility Criteria

  • 1\. Age ≥ 18 years at the time of informed consent and have provided signed informed consent for the trial.
  • 2\. Willing and able to comply with all aspects of the protocol.
  • 3\. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1.
  • 4\. Life expectancy ≥ 3 months.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lymphoma Trials on Trialify →